Foghorn Therapeutics uses a structure‑based chemistry platform combined with chemoproteomics and AI‑augmented medicinal chemistry to design selective small‑molecule inhibitors of chromatin‑regulating proteins such as bromodomains, methyltransferases, and demethylases. The company advances these compounds through preclinical validation to IND‑ready candidates, providing epigenetic drug assets to pharmaceutical, biotech, and academic partners.
Funding
$110M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease-driving gene expression programs are regulated by chromatin-modifying proteins that lack high‑affinity, selective small‑molecule ligands. Conventional drug discovery pipelines struggle to address these epigenetic targets, leaving a therapeutic gap for cancers and other serious conditions that depend on dysregulated chromatin machinery.
Solution
Foghorn Therapeutics applies a chemistry‑driven platform to design and optimize small‑molecule inhibitors that bind with high selectivity to chromatin regulators such as readers, writers, and erasers. By integrating structural biology, chemoproteomics, and predictive modeling, the company generates compounds that modulate specific gene‑expression pathways implicated in disease. These inhibitors are advanced through preclinical validation, including cellular potency, target engagement assays, and in vivo efficacy models, to produce IND‑ready candidates. The approach expands the druggable genome, enabling therapeutic intervention in pathways previously considered inaccessible.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking epigenetic drug candidates, as well as academic research groups focused on chromatin biology and oncology.
Features
- Structure‑based design pipeline targeting chromatin‑associated protein domains (e.g., bromodomains, methyltransferases, demethylases)
- Proprietary chemoproteomics platform for rapid target validation and off‑target profiling to ensure high selectivity
- AI‑augmented medicinal chemistry workflow that accelerates hit‑to‑lead optimization while maintaining drug‑like properties
- Integrated cellular assays that measure transcriptional reprogramming and downstream phenotypic effects
- In vivo disease models demonstrating target‑dependent tumor regression and pharmacodynamic biomarker modulation
- IND‑enabling package including GLP toxicology, formulation development, and regulatory documentation
- Collaborative partnership framework allowing co‑development with pharmaceutical and biotech companies